Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 54Terminated 16Active not recruiting 15Unknown 10Recruiting 6Withdrawn 4Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Specimen Handling 19Biopsy 13Magnetic Resonance Spectroscopy 11Cyclophosphamide 4X-Rays 3Vincristine 3Nivolumab 3Doxorubicin 3venetoclax 2trastuzumab deruxtecan 2decitabine and cedazuridine drug combination 2Taxes 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Prednisone 2Ipilimumab 2Cetuximab 2CTLA-4 Antigen 2Azacitidine 2Actinium 2(225)Ac-DOTA-c(RGDyK) 2sargramostim 1relatlimab 1prednylidene 1olaparib 1neratinib 1mirdametinib 1ipatasertib 1iadademstat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × NIH × Rituximab × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡